Photodynamic therapy (PDT) is a modality of caner treatment that uses a combination of photosensitizer and tissuepenetrating laser light. After laser irradiation, singlet oxygen is produced and induces cytotoxicity. Benzoporphyrin derivative monoacid ring A (BPD-MA) is a second-generation photosensitizer, and is clinically using for the treatment of agerelated macular degeneration. Since BPD-MA is a hydrophobic property, it is formulated as a liposomal drug. In the previous study, we established rather stable liposomal BPD-MA, where liposome was composed of dipalmitoylphosphatidylcholine (DPPC), palmitoyloleoylphosphatidylcholine (POPC), dipalmitoylphosphatidylglycerol (DPPG), cholesterol, and BPD-MA (10/10/2.5/10/0.3 as molar ratio). 1) In the present study, to enhance the accumulation of liposomal BPD-MA in tumor tissues, BPD-MA liposome was modified with polyethylene glycol (PEG), since PEG-liposomes are know to have long-circulating characteristics after systemic injection, and to accumulate passively in tumor in tumor-bearing animals. 2, 3) As a result, we observed the enhanced accumulation of BPD-MA in tumor tissue by PEGylated liposome, but the therapeutic efficacy was unexpectedly rather decreased by PEG-modification.
BPD-MA-entrapped PEG-liposome (PEG-LipBPD-MA) and BPD-MA-entrapped non-modified liposome (ContLipBPD-MA) were composed of DPPC, POPC, cholesterol, DPPG, and BPD-MA (10/10/10/2.5/0.3 as molar ratio), and were sized at 100-nm in diameter by extrusion technique. In animal experiments, the animals were cared for according to the Guidelines for the Care and Use of Laboratory Animals of the University of Shizuoka.
For the purpose of avoiding reticulo-endothelial system (RES)-trapping of macromolecular drugs, polymer drugs, and drug carriers in systemic usage, PEGylation has been widely applied, including polymer conjugated photosensitizers for PDT. 4, 5) The feature of long-circulation causes enhanced accumulation of such drugs and carriers in tumor tissues because angiogenic vasculature in tumor tissue is quite leaky and macromolecules are easily accumulate in the interstitial tissues of the tumor due to the enhanced permeability and retention (EPR) effect.
6,7)
Therefore, we first examined BPD-MA accumulation in tumor at 3 h after injection of Cont-LipBPD-MA and PEGLipBPD-MA in tumor-beaing mice. Meth-A sarcoma cells (1ϫ10 6 cells/0.2 ml) were injected s.c. into BALB/c mice (Japan SLC). Seven days after implantation of the tumor, the tumor-bearing mice were injected i.v. with liposomal BPD-MA (2 mg/kg as BPD-MA). The mice were sacrificed at 3 h after injection of the liposomal BPD-MA. Then, BPD-MA was extracted from the tumor, and analyzed by using HPLC (Shimadzu, Japan). PEGylation of liposomes actually greatly enhanced tumor accumulation of BPD-MA as expected (Fig. 1) .
Next, we examined the suppression of tumor growth after PDT by use of these liposomal formulations. Liposomal BPD-MA (0.5 mg/kg as BPD-MA, instead of 2 mg/kg) was injected into tumor-bearing mice similarly prepared to the distribution assay at day 7 after tumor implantation. PDT treatment was performed by irradiation at the tumor site with 689 nm laser light (150 J/cm 2 , 0.25 W) at 3 h after injection of liposomal BPD-MA. At day 16 after tumor implantation, tumor sizes were examined (Fig. 2) .
The result is unexpected and quite interesting, that tumor growth suppression was more obvious for Cont-LipBPD-MA-injected group after treatment of PDT than for PEG- Fig. 1 . BPD-MA Accumulation in Tumor Liposomal was injected into Meth A-sarcoma-bearing mice (nϭ5). At 3 h after injection, tumor was excised and BPD-MA amount was determined. Significant difference; * * , pϽ0.001.
Fig. 2. Tumor Growth Suppression by PDT with Liposomal BPD-MA
LipBPD-MA-injected group, although the total amount of BPD-MA in tumor tissue is more than 5-fold higher for the latter than former as shown in Fig. 1 . Corresponding to the tumor growth suppression, the mean lifetime of tumor-bearing mice (nϭ5) was 30.6, 37.0, and 29.4 d for non-treatment, Cont-LipBPD-MA-PDT, and PEG-LipBPD-MA-PDT groups, respectively.
Recently, it was revealed that anti-cancer drugs administered with repeated low dose, namely metronomic dosing, damage angiogenic endothelial cells as well as tumor cells. 8, 9) Interestingly, PEG-liposomal adriamycin, Doxil, is thought to damage angiogenic cells besides its direct toxicity against tumor cells, because tumor tissues including neovessels are exposed to lower dose of ADM for longer time than the case of free ADM-treatment: Long-circulating liposomal anti-cancer drugs may behave similar to those administered metronomic dosing. This evidence strongly suggests that liposomal carriers release BPD-MA slowly at the tumor site. PEG-liposomes encapsulating anti-cancer drugs are useful for passive targeting, and the drugs accumulated in tumor tissue act for longer period time to tumor cells. In PDT, however, only the photosensitizers taken up by tumor cells damage tumor cells when laser irradiation is performed. In the present study, we scheduled 3 h for allowing liposomal BPD-MA to interact tumor cells. Therefore, PEGylation effect was not positively observed but reduced the susceptibility. It is possible, if we allow longer period of time for the interaction, PEGylation effect becomes positive.
We previously observed that glucuronate-modified liposomal BPD-MA strongly suppressed tumor growth in tumorbearing mice after laser irradiation at 5 h post-injection. 10) In this case, the enhanced therapeutic efficacy may be explained by that 5 h is enough to allow BPD-MA-delivering to tumor cells, and/or that glucuronate-modification does not protect the interaction of liposome to tumor cells.
In conclusion, although PEGylation of liposome enhances passive accumulation of liposomal drugs in tumor tissues, it does not always beneficial for therapy, especially in case of PDT, in which fast accumulation of photosensitizers in tumor cells is critical. However, it is possible that the conjugation of some ligands or antibodies specific for target cells to PEGliosome overcome the problem.
